Next Article in Journal
The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ NaV1.5 Mutant of the Long QT Type 3 Syndrome
Previous Article in Journal
Regulation of Interferon Induction by the Ubiquitin-Like Modifier FAT10
Open AccessArticle

An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis

1
INSERM, U1043, CNRS, U5282, Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse-Purpan, F-31300 Toulouse, France
2
CNRS, UMR 5623, Université de Toulouse, UPS, Laboratoire des Interactions Moléculaires et Réactivité Chimique et Photochimique, IMRCP, 118 route de Narbonne, CEDEX 9, F-31062 Toulouse, France
3
CNRS, UPR 8241, Laboratoire de Chimie de Coordination, 205 route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France
4
LCC-CNRS, Université de Toulouse, CNRS, 31400 Toulouse, France
5
Imavita S.A.S., Canal Biotech 1, 3 rue des Satellites, Parc Technologique du Canal, F-31400 Toulouse, France
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(6), 949; https://doi.org/10.3390/biom10060949
Received: 5 May 2020 / Revised: 5 June 2020 / Accepted: 15 June 2020 / Published: 23 June 2020
(This article belongs to the Section Molecular Medicine)
Dendrimers are nanosized, arborescent macromolecules synthesized in a stepwise fashion with attractive degrees of functionality and structure definition. This is one of the reasons why they are widely used for biomedical applications. Previously, we have shown that a poly(phosphorhydrazone) (PPH) dendrimer capped with anionic azabisphosphonate groups (so-called ABP dendrimer) has immuno-modulatory and anti-inflammatory properties towards human immune cells in vitro. Thereafter, we have shown that the ABP dendrimer has a promising therapeutic efficacy to treat models of acute and chronic inflammatory disorders in animal models. In these models, the active pharmaceutical ingredient was administered systematically (intravenous and oral administrations), but also loco-regionally in the vitreous tissue. Herein, we assessed the therapeutic efficacy of the ABP dendrimer in the preclinical mouse model of psoriasis induced by imiquimod. The ABP dendrimer was administered in phosphate-buffered saline solution via either systemic injection or topical application. We show that the topical application enabled the control of both the clinical and histopathological scores, and the control of the infiltration of macrophages in the skin of treated mice. View Full-Text
Keywords: dendrimer; drug candidate; imiquimod mouse model; inflammation; phosphonate; preclinical efficacy; psoriasis; topical application dendrimer; drug candidate; imiquimod mouse model; inflammation; phosphonate; preclinical efficacy; psoriasis; topical application
Show Figures

Figure 1

MDPI and ACS Style

Jebbawi, R.; Oukhrib, A.; Clement, E.; Blanzat, M.; Turrin, C.-O.; Caminade, A.-M.; Lacoste, E.; Fruchon, S.; Poupot, R. An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis. Biomolecules 2020, 10, 949.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop